Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Luca Issi

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.

Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.

Investors Business Daily

Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.

Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.

Investors Business Daily

Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test

Moderna stock surged Monday, nearing its first breakout in over a year, after launching a third study of its cancer vaccine.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues

Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.

Investors Business Daily

Verve Stock Soars On $250 Million Eli Lilly Deal

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

Investors Business Daily

Alnylam Is Now 'One Of The Most Binary' Stories In Biotech. Why The FDA Rejected Its Heart Drug.

Alnylam stock skidded Monday after the FDA rejected its drug, Onpattro, as a treatment for patients with a heart disease.

Investors Business Daily

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer

Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.

Investors Business Daily

Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

Investors Business Daily

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million

Eli Lilly inked a gene-editing collaboration with Verve Therapeutics that gave the young biotech "pharma validation."

Investors Business Daily

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease

Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.

Investors Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Investors Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.

Investors Business Daily

FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Drops

The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.